Development and evaluation of dexamethasone nanomicelles with potential for treating posterior Uveitis after topical application

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 4, 2015, Pages 215-227

  Patel, Soohi ^a   Garapati, Chandrasekhar ^a   Chowdhury, Pallabita ^a   Gupta, Himanshu ^a   Nesamony, Jerry ^a   Nauli, Surya ^b   Boddu, Sai H S ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DRUG CARRIER; MACROGOL STEARATE; NANOMICELLE; POLYSORBATE 80; UNCLASSIFIED DRUG; GLUCOCORTICOID; MICELLE; NANOPARTICLE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG TISSUE LEVEL; FILTRATION; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; SINGLE DRUG DOSE; SURFACE CHARGE; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; UVEITIS; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; MICELLE; PATHOLOGY; PROCEDURES; RABBIT; SOLUBILITY; UVEITIS, POSTERIOR;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; GLUCOCORTICOIDS; MALE; MICELLES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; RABBITS; SOLUBILITY; UVEITIS, POSTERIOR;

EID: 84929657478     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0152     Document Type: Article

References (34)

1. Gritz, D.C., and Wong, I.G. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 111:491-500; discussion 500, 2004.
2. de Boer, J., Wulffraat, N., and Rothova, A. Visual loss in uveitis of childhood. Br. J. Ophthalmol. 87:879-884, 2003.
3. Suhler, E.B., Lloyd, M.J., Choi, D., Rosenbaum, J.T., and Austin, D.F. Incidence and prevalence of uveitis in Veter-ans Affairs Medical Centers of the Pacific Northwest. Am. J. Ophthalmol. 146:890-896.e8, 2008.
4. Janoria, K.G., Gunda, S., Boddu, S.H., and Mitra, A.K. Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv. 4:371-388, 2007.
5. Boddu, S.H.S. Polymeric nanoparticles for ophthalmic drug delivery: an update on research and patenting activity. Recent Patents Nanomed. 2:96-112, 2012.
6. Boddu, S.H., Jwala, J., Vaishya, R., et al. Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. J. Ocul. Pharmacol. Ther. 26:37-48, 2010.
7. Arcinue, C.A., Cerón, O.M., and Foster, C.S. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J. Ocul. Pharmacol. Ther. 29:501-507, 2013.
8. Kompella, U.B., and Edelhauser, H.F. Drug Product Development for the Back of the Eye. AAPS Advances in the Pharmaceutical Sciences Series. Boston: American Association of Pharmaceutical Scientists, Springer; 2011.
9. Mateo, C., Alkabes, M., and Burés-Jelstrup, A. Scleral fixation of dexamethasone intravitreal implant (OZURDEX) in a case of angle-supported lens implantation. Int. Ophthalmol. 34:661-665, 2014.
10. Loftsson, T., Hreinsdottir, D., and Stefansson, E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J. Pharm. Pharmacol. 59:629-635, 2007.
11. Loftsson, T., SigurCsson, H., KonráCsdottir, F., Gisladottir, S., Jansook, P., and Stefansson, E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie. 63:171-179, 2008.
12. Loftsson, T., Sigurdsson, H.H., Hreinsdottir, D., Konrádsdo ttir, F., and Stefánsson, E. Dexamethasone delivery to posterior segment of the eye. J. Incl. Phenom. Macrocycl. Chem. 57:585-589, 2007.
13. Ni, Z., and Hui, P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica. 223: 401-410, 2009.
14. Vadlapudi, A.D., and Mitra, A.K. Nanomicelles: an emerging platform for drug delivery to the eye. Ther. Deliv. 4:1-3, 2013.
15. Trivedi, R., and Kompella, U.B. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond). 5:485-505, 2010.
16. Earla, R., Boddu, S.H., Cholkar, K., Hariharan, S., Jwala, J., and Mitra, A.K. Development and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids-quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry. J. Pharm. Biomed. Anal. 52:525-533, 2010.
17. Velagaleti, P., Anglade, E., Khan, J., Gilger, B., and Mitra, A. Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior &posterior segments of the eye. Drug Deliv. Technol. 10:42-47, 2010.
18. Jiao, J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv. Drug Deliv. Rev. 60:1663-1673, 2008.
19. Hazleton, L.W. Relation of surface active properties of irritation of the rabbit eye. Proc. Sci. Sect. Toilet Goods Assoc. 17:1-5, 1952.
20. Boddu, S., Bonam, S.P., Wei, Y., and Alexander, K. Preparation and in vitro evaluation of a pluronic lecithin organogel containing ricinoleic acid for transdermal delivery. Int. J. Pharm. Compd. 18:256-261, 2013.
21. Bondarenko, A.I., Malli, R., and Graier, W.F. The GPR55 agonist lysophosphatidylinositol directly activates intermediate-conductance Ca2+ -activated K+ channels. Pflugers Arch. 462:245-255, 2011.
22. Prajapati, S.T., Joshi, H.A., and Patel, C.N. Preparation and characterization of self-microemulsifying drug delivery system of olmesartan medoxomil for bioavailability improvement. J. Pharm. 2013:Article ID 728425, 2013.
23. Mitra, A. K., Velagaleti, P. R., and Natesan, S.: Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors. U.S. Patent 8, 435, 544. 2013.
24. Nesamony, J., Kalra, A., Majrad, M.S., et al. Development and characterization of nanostructured mists with potential for actively targeting poorly water-soluble compounds into the lungs. Pharm. Res. 30:2625-2639, 2013.
25. Wilhelmus, K.R. The draize eye test. Surv. Ophthalmol. 45:493-515, 2001.
26. Boddu, S.H., Gupta, H., and Bonam, S.P. Preclinical evaluation of a ricinoleic acid poloxamer gel system for transdermal eyelid delivery. Int. J. Pharm. 470:158-161, 2014.
27. Li, L., and Tan, Y.B. Preparation and properties of mixed micelles made of Pluronic polymer and PEG-PE. J. Colloid Interface Sci. 317:326-331, 2008.
28. Gómez-Gaete, C., Tsapis, N., Besnard, M., Bochot, A., and Fattal, E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int. J. Pharm. 331:153-159, 2007.
29. Gan, L., Han, S., Shen, J., et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int. J. Pharm. 396:179-187, 2010.
30. Song, H., Geng, H., Ruan, J., et al. Development of Polysorbate 80/Phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models. Nanoscale Res. Lett. 6:1-12, 2011.
31. Weijtens, O., Schoemaker, R.C., Romijn, F.P.H.T.M., Cohen, A.F., Lentjes, E.G.W.M., and van Meurs, J.C. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 109:1887-1891, 2002.
32. Kompella, U.B., Amrite, A.C., Pacha Ravi, R., and Durazo, S.A. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog. Retin. Eye Res. 36:172-198, 2013.
33. Chang-Lin, J.-E., Attar, M., Acheampong, A.A., et al. Pharmacokinetics and pharmacodynamics of a sustainedrelease dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci. 52:80-86, 2011.
34. Weijtens, O., Feron, E.J., Schoemaker, R.C., et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am. J. Ophthalmol. 128: 192-197, 1999.